Helus Pharma Inc.(HELP)

Medical - Pharmaceuticals · Toronto, ON

$10.64-0.78 (-6.83%)

Delayed quote: Oct 6, 2026, 3:35 PM EDT

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T19:36:55.792Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:36:55.792Z.

Quote observation: 2026-10-06T19:35:13.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 659,510,845
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 166,165,362
TTM revenue · period ending 2026-06-30: 0

FMP input reference: 934548bd97ab8c390298f716fcf622fc2d1107cfab085c47b2b47650fd31fbc6

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

HELP EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

HELP Competitors' EV/Sales Ratio

HELP

Helus Pharma Inc.

Current

Market Cap

$659.51M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

STLN

Starling Oncology, Inc.

vs HELP

Market Cap

$658.89M

EV/Sales Ratio

1.23x

TTM Avg

1.16x

3Y Avg

1.16x

5Y Avg

1.16x

FDMT

4D Molecular Therapeutics, Inc.

vs HELP

Market Cap

$660.25M

EV/Sales Ratio

6.84x

TTM Avg

3080.33x

3Y Avg

3087.28x

5Y Avg

1898.38x

MDXG

MiMedx Group, Inc.

vs HELP

Market Cap

$660.28M

EV/Sales Ratio

1.48x

TTM Avg

1.59x

3Y Avg

2.50x

5Y Avg

2.28x

ANNX

Annexon, Inc.

vs HELP

Market Cap

$665.22M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVBP

ArriVent BioPharma, Inc.

vs HELP

Market Cap

$682.79M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SLDB

Solid Biosciences Inc.

vs HELP

Market Cap

$676.87M

EV/Sales Ratio

N/A

TTM Avg

2.20x

3Y Avg

6.98x

5Y Avg

6.98x

PRME

Prime Medicine, Inc.

vs HELP

Market Cap

$636.50M

EV/Sales Ratio

172.24x

TTM Avg

136.19x

3Y Avg

307.18x

5Y Avg

307.18x

FTH

Faeth Therapeutics, Inc.

vs HELP

Market Cap

$683.91M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VSTM

Verastem, Inc.

vs HELP

Market Cap

$684.40M

EV/Sales Ratio

7.23x

TTM Avg

41.09x

3Y Avg

46.52x

5Y Avg

55.30x

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Helus Pharma Inc. (HELP)	$659.51M	N/A	N/A	N/A	N/A
Starling Oncology, Inc. (STLN)vs ›	$658.89M	1.23x	1.16x	1.16x	1.16x
4D Molecular Therapeutics, Inc. (FDMT)vs ›	$660.25M	6.84x	3080.33x	3087.28x	1898.38x
MiMedx Group, Inc. (MDXG)vs ›	$660.28M	1.48x	1.59x	2.50x	2.28x
Annexon, Inc. (ANNX)vs ›	$665.22M	N/A	N/A	N/A	N/A
ArriVent BioPharma, Inc. (AVBP)vs ›	$682.79M	N/A	N/A	N/A	N/A
Solid Biosciences Inc. (SLDB)vs ›	$676.87M	N/A	2.20x	6.98x	6.98x
Prime Medicine, Inc. (PRME)vs ›	$636.50M	172.24x	136.19x	307.18x	307.18x
Faeth Therapeutics, Inc. (FTH)vs ›	$683.91M	N/A	N/A	N/A	N/A
Verastem, Inc. (VSTM)vs ›	$684.40M	7.23x	41.09x	46.52x	55.30x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics